MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Neuropsychopharmacology reports December 1, 2024 Ghada Shahrour, Kainat Sohail, Safa Elrais et al. 21 citations
MDMA-assisted psychotherapy (MDMA-AT) significantly reduces PTSD symptoms and improves response and remission rates in people with chronic, treatment-resistant PTSD, according to a meta-analysis of nine randomized controlled trials involving 297 participants. The treatment led to a large reduction in clinician-rated PTSD severity scores compared to control conditions (inactive MDMA doses or placebo). Patients receiving MDMA-AT were about 1.6 times more likely to show a meaningful response and over twice as likely to achieve remission. No significant differences were found between groups in rates of treatment-emergent adverse events, severe adverse events, or suicidal ideation, indicating a favorable safety profile.